Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Influence of Expression Plasmid of Connective Tissue Growth Factor and Tissue Inhibitor of Metalloproteinase-1 shRNA on Hepatic Precancerous Fibrosis in Rats

  • Zhang, Qun (Division of Infectious Diseases, Affiliated Zhongda Hospital of Southeast University) ;
  • Shu, Fu-li (Dept. Infectious Diseases, Affiliated Hospital of Luzhou Medical College) ;
  • Jiang, Yu-Feng (Dept. Infectious Diseases, Affiliated Hospital of Luzhou Medical College) ;
  • Huang, Xin-En (Dept. of Chemotherapy, Jiangsu Cancer Hospital & Research Institute)
  • Published : 2015.11.04
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In this study, influence caused by expression plasmids of connective tissue growth factor (CTGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) short hairpin RNA (shRNA) on mRNA expression of CTGF,TIMP-1,procol-${\alpha}1$ and PCIII in hepatic tissue with hepatic fibrosis, a precancerous condition, in rats is analyzed. Materials and Methods: To screen and construct shRNA expression plasimid which effectively interferes RNA targets of CTGF and TIMP-1 in rats. 50 cleaning Wistar male rats are allocated randomly at 5 different groups after precancerous fibrosis models and then injection of shRNA expression plasimids. Plasmid psiRNA-GFP-Com (CTGF and TIMP-1 included), psiRNA-GFP-CTGF, psiRNA-GFP-TIMP-1 and psiRNA-DUO-GFPzeo of blank plasmid are injected at group A, B, C and D, respectively, and as model control group that none plasimid is injected at group E. In 2 weeks after last injection, to hepatic tissue at different groups, protein expression of CTGF, TIMP-1, procol-${\alpha}1$ and PC III is tested by immunohistochemical method and,mRNA expression of CTGF,TIMP-1,procol-${\alpha}1$ and PCIII is measured by real-time PCR. One-way ANOVA is used to comparison between-groups. Results: Compared with model group, there is no obvious difference of mRNA expression among CTGF,TIMP-1,procol-${\alpha}1$, PC III and of protein expression among CTGF, TIMP-1, procol-${\alpha}1$, PC III in hepatic tissue at group injected with blank plasmid. Expression quantity of mRNA of CTGF, TIMP-1, procol-${\alpha}1$ and PCIII at group A, B and C decreases, protein expression of CTGF, TIMP-1, procol-${\alpha}1$, PC III in hepatic tissue is lower, where the inhibition of combination RNA interference group (group A) on procol-${\alpha}1$ mRNA transcription and procol-${\alpha}1$ protein expression is superior to that of single interference group (group B and C) (P<0.01 or P<0.05). Conclusions: RNA interference on CTGF and/or TIMP-1 is obviously a inhibiting factor for mRNA and protein expression of CTGF, TIMP-1, procol-${\alpha}1$ and PCIII. Combination RNA interference on genes of CTGF and TIMP-1 is superior to that of single RNA interference, and this could be a contribution for prevention of precancerous condition.

Keywords

References

  1. Giannelli G, Mazzocca A, Fransvea E, et al (2011). Inhibiting TGF-${\beta}$1 signaling in hepatocelluar carcnoma. Biochim Biophys Acta, 1815, 214-23.
  2. Hepatic fibrosis group of chinese society of hepatology (2002). consensus about evaluating hepatic fibrosis diagnosis and efficacy. Chinese J Hepatol, 10, 327-328.
  3. Hemmann S, Graf J, Roderfeld M, et al (2007). Expression of MMPs and TIMPs in liver fibrosis-asystematic review with special emphasis on anti-fibrotic strategies. J Hepatol, 46, 955-75. https://doi.org/10.1016/j.jhep.2007.02.003
  4. Jiang YF, Huang F, Zhang JJ, et al (2011). RNA interference targets on connective tissue growth factor and tissue inhibitor tissue inhibtor of metalloproteinase-1 in vitro. J Clin Hepatol, 14, 246-8.
  5. Jiang YF, Liu JQ, Zhang JJ, et al (2011). Construction of two different hepatic fibrosis-related cytokines shRNA recombinant plasmid. Chongqing Med, 40, 2341-2.
  6. Jiang YF, Zhou DJ, Zhang JJ, et al (2012). Construction of dual RNA interference plasmid of hepatic fibrosis-related cytokines and study on transfection of hepatic stellate cells. J Clin Hepatol, 15, 516-9.
  7. Kuang SL, Hu B (2008). Development of study on model of hepatic fibrosis in rats. Laboratory Animal Comparative Med, 28, 62-66.
  8. Lee UE, Friedman SL (2011). Mechanisms of hepatic fibrogenisis. Best Pract Res Clin Gastroenterol, 25, 195-206. https://doi.org/10.1016/j.bpg.2011.02.005
  9. Rettiq GR,Behlke MA (2012). Progress toward in vivo use of siRNA-II. Mol Ther, 20, 483-512. https://doi.org/10.1038/mt.2011.263
  10. Tache D,Boqdan F,Pisoschi C, et al (2011). Evidence for the involvement of TGF-${\beta}$1-CTGF axis in liver fibrogenisis secondary to hepatic viral infection. Rom J Morphol Embryol, 52, 409-12.
  11. Xu LM (2010). Update on hepatic fibrosis research. J Clin Hepatol, 18, 563-565.
  12. Yang J,Zheng J,Wu L, et al (2011). MDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-${\beta}$1/Smad pathway and altering the MMP2/TIMP2 ratio in rats. PLoS One,6, 27710. https://doi.org/10.1371/journal.pone.0027710
  13. Yan X,Chen YG (2011). Smad7:not only a regulator,but also a cross-talk mediator of TGF-${\beta}$ signaling. Biochem J, 434, 1-10. https://doi.org/10.1042/BJ20101827

Cited by

  1. RNA Interference Mediated Silencing of Tissue Factor in Human Umbilical Vein Endothelial Cells vol.08, pp.05, 2018, https://doi.org/10.4236/ojog.2018.85054